COVID-19

Pediatric and obstetric groups expand high-risk criteria and extend vaccination windows as federal vaccine guidance remains unsettled.

The updated formula targets the JN. 1-lineage XFG variant and begins shipping immediately to pharmacies, hospitals, and clinics nationwide.

A lesser-known viral protein may drive both the hyperinflammation and vascular damage seen in severe and long COVID-19.

Night shift and insomnia may triple long-COVID risk; learn how chronic insomnia and long-COVID links affect health workers and prevention.

New recommendations move noncore shots to shared clinical decision-making, but a court stay keeps day-to-day pharmacy practice unchanged.

Jerry P. Abraham, MD, MPH, CMQ, discusses the persistent risks of COVID-19 and how a newly approved postexposure prophylaxis option is reshaping pharmacists' role in prevention.

FDA clears ensitrelvir oral postexposure pill to prevent symptomatic COVID-19 after close contact, cutting infections in household trial with comparable safety.

Australian trial shows bivalent mRNA COVID-19 booster lifts antibodies more than protein vaccine, yet both cut infection similarly over 12 months.

New PET imaging data show reduced dopamine nerve terminal density in patients with long COVID, correlating with fatigue, motor slowing, and memory problems.

The authors said these data support the safety of current coadministration practice.

COVID-19 boosters can also neutralize certain bat and pangolin coronaviruses, while immune "imprinting" from a person's first viral exposure limits how well that protection adapts to newer variants.

Interim data, briefly held back from the CDC’s weekly report, show the reformulated shot added meaningful protection even among adults with substantial existing immunity.

The findings add to a growing body of evidence supporting metformin's role as a preventive strategy against postacute sequelae of COVID-19.

Temperature differences between exhaled air and ambient environments significantly affect how respiratory aerosols disperse.

PET scans show long COVID mood and brain fog link to limbic activity, not widespread brain inflammation, reshaping COVID-19 treatment targets.

The FDA approved the oral antiviral ensitrelvir (Xocova; Shionogi & Co, Ltd) for post-exposure prophylaxis (PEP) of COVID‑19 in adults and adolescents 12 years and older.

New household data show recent COVID-19 shots cut at-home spread by 43%, strengthening pharmacist counseling on staying up to date.

A large prospective cohort study offers pharmacists and clinicians new data to consider when counseling patients on the long-term value of early antiviral treatment.

The drug is currently under priority review by the FDA with a final decision expected by June 16, 2026.

Phase 3 SCORPIO-PEP trial shows ensitrelvir cuts symptomatic COVID-19 after household exposure, boosting postexposure prophylaxis options for high-risk patients.

A new study describes the high symptom burden carried by pediatric long COVID patients and highlights integrative medicine's role in their care.

New trials show Pfizer’s Paxlovid (nirmatrelvir-ritonavir) speeds COVID-19 recovery in vaccinated patients, while hospitalization benefits fade.

New Yale University research offers reassurance for pregnant patients and their clinicians, although evidence of lasting structural damage remains a concern.

Post–COVID-19 access gaps fuel unsafe, unregulated Botox and cosmetic injections; trained pharmacists can deliver regulated botulinum toxin injectables through voluntary specialization.

Early immune signals can program longer-lasting lung-resident T cells—a potential breakthrough for influenza and COVID-19 vaccine design.